|
horsechute
|
 |
« Reply #4 on: 10-25-09 at 08:36 pm » |
|
I was hoping we could avoid this, but at any rate, here is what you said:
"Let me guess, your ninth ingredient is the transdermal-ing goop, and is the same as in any other transdermal medication. So, its use is not novel, and the results of its combination with the other eight is obvious."
Let's skip the metabolite issue and assume your "guess" is correct, that the ninth ingredient is, as you say, a "transermal-ing goop" that is already known in the art. We'll assume it is polypropylene glycol.
Polyproplene glycol is known in the art for transdermally administering a compound for treating herpes in the medication known as Lidoderm. See claim 9 of USPN 5411738:
"A gel formulation for treatment of pain from herpes zoster or post-herpetic neuralgia comprising: from about 70 to 90 weight % of propylene glycol; from about 1 to 20 weight % of lidocaine; from about 2 to 20 weight % of a non-ionic surfactant comprising physiologically acceptable sorbitan esters; from about 0.1 to 5 weight % of a physiologically acceptable gelling agent; and not more than about a total of 10 weight % of physiologically acceptable excipients."
Now, just because Polypropylene glycol, admittedly a well known compound, is known to be a transdermal carrier for a compound for treating shingles does not mean that a person cannot receive a patent for combining it with a some other known compound, in this case, for arguments sake, apparently some kind of known nutrient. Say the person took a known combination of 8 (or 9) different vitamins to be effective for treating arthritis. Now say our inventor discovered, low and behold, that you can obtain a much more potent administration of the compound to the body by administering it transdermally. Now, assume that they found that Polyropylene glycol would be an effective carrier. Are they precluded from obtaining a patent on this combination of compounds, just because some someone used polyproplene glycol to administer a compound for treating shingles? Not at all. People do this sort of thing all the time (in fact, hundreds, according to a rough lexis/patent search I just did). It is not the carrier in patches that administer substances such as fentanyl, nitroglycerin, clonidine, or lidoderm, to mention a few, which makes their patch patentable, it is the discovery that the combination of the active ingredients may, when combined with a suitable carrier, be administered transdermally that makes the combination, when properly claimed, patentable.
Note, I have made every assumption in your favor, and to tell you the truth, I would probably need more information before I even said what I just did.
|